Capricor EVP sells 900 shares after option exercise
Capricor Therapeutics EVP and General Counsel Karen Krasney reported routine insider transactions involving company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Capricor Therapeutics EVP and General Counsel Karen Krasney reported routine insider transactions involving company stock. She exercised stock options to acquire a total of 900 shares of common stock at an exercise price of $3.18 per share, then sold 900 shares in open-market transactions at $30.00 per share pursuant to a preplanned Rule 10b5-1 trading plan adopted in December 2025. Following these trades, she directly holds 30,547 shares of Capricor common stock.
Insider Trade Summary
Exercise and Sale: 900 shares ($24K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Krasney Karen
Role
EVP, GENERAL COUNSEL
Sold
900 shs ($27K)
Approx. gross sale proceeds
$27K
Approx. exercise cost
$3K
Approx. pre-tax spread
$24K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 400 | $0.00 | $0.00 |
| Exercise | Common Stock | 400 | $3.18 | $1K |
| Sale | Common Stock | 400 | $30.00 | $12K |
| Exercise | Stock Option (Right to Buy) | 500 | $0.00 | $0.00 |
| Exercise | Common Stock | 500 | $3.18 | $2K |
| Sale | Common Stock | 500 | $30.00 | $15K |
Holdings After Transaction:
Stock Option (Right to Buy) — 55,361 contracts (Direct);
Common Stock — 30,547 shares (Direct)
Footnotes (2)
- F1. Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2. Shares vested 1/48th on the first day of each month commencing February 1, 2022.
Key Figures
Shares sold: 900 shares
Sale price: $30.00 per share
Options exercised: 900 shares
+4 more
7 metrics
Shares sold
900 shares
Open-market sales at $30.00 per share in June 2026
Sale price
$30.00 per share
Common stock sold in two open-market transactions
Options exercised
900 shares
Stock options exercised at $3.18 per share
Exercise price
$3.18 per share
Stock Option (Right to Buy) conversion into common stock
Post-transaction holdings
30,547 shares
Direct common stock ownership after reported trades
Remaining options
55,361 options
Stock options outstanding after option exercises
Net share change
-900 shares
Net of 900 shares sold versus 900 acquired in exercises
Key Terms
Rule 10b5-1, Stock Option (Right to Buy), open-market sale, derivative exercise/conversion, +1 more
5 terms
Rule 10b5-1 regulatory
"Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
vested 1/48th financial
"Shares vested 1/48th on the first day of each month"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did CAPR executive Karen Krasney report on this Form 4?
Karen Krasney reported exercising stock options for 900 Capricor shares at $3.18 and selling 900 shares at $30.00. The filing shows both the option exercises and matching open-market sales over two days in June 2026.
What stock options did Karen Krasney exercise in this CAPR Form 4 filing?
She exercised stock options covering 900 Capricor common shares at an exercise price of $3.18 per share. These options are described as "Stock Option (Right to Buy)" and were originally scheduled to vest in monthly installments starting February 1, 2022.
Were Karen Krasney’s CAPR stock sales made under a Rule 10b5-1 trading plan?
Yes. The Form 4 footnote states the Capricor shares were sold pursuant to a Rule 10b5-1 trading plan adopted in December 2025. Such preplanned arrangements are designed to execute trades automatically according to preset instructions.
What is Karen Krasney’s role at Capricor Therapeutics (CAPR)?
Karen Krasney is listed as an officer of Capricor Therapeutics, serving as Executive Vice President and General Counsel. Her position is identified in the Form 4 reporting these insider stock option exercises and share sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
